Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.

NCT Number	NCT07059091
Lead Sponsor	Johns Hopkins University Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., American Lung Association Asthma Clinical Research Centers, American Lung Association
Conditions	Chronic Obstructive Pulmonary Disease (COPD), Allergies
Enrollment	334 participants
Start Date	2026-02-12
Primary Completion	2031-01 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-02-17